Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Next Previous
Search
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary) ; Apremilast
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms POETYK-PSO-2
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 16 Jan 2024 Results from NCT04036435, NCT03611751 and NCT03624127, evaluating deucravacitinib safety and efficacy over 2 years in patients, published in the British Journal of Dermatology
  • 18 Dec 2023 Results from POETYK PSO-1 and PSO-2 evaluating the efficacy and safety of deucravacitinib in scalp psoriasis , published in the Journal of the American Academy of Dermatology
  • 15 Nov 2023 Results of pooled analysis from POETYK PSO-1 and PSO-2 trials assessing efficacy of Deucravacitinib, presented at the ACR Convergence 2023

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top